Curasight AS (XSAT:CURAS) Total Operating Expense: kr6.61 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CURAS Curasight AS XSAT:CURAS
24 GF Score
Price kr16.75
! 2 Warning Signs
View Full Analysis

What is Curasight AS Total Operating Expense?

Curasight AS XSAT:CURAS -1.47% 24 Total Operating Expense is kr6.61 Mil as of Mar. 2026. GuruFocus rates XSAT:CURAS with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Curasight AS's Total Operating Expense for the three months ended in Mar. 2026 was kr2.20 Mil. Curasight AS's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr6.61 Mil.

Curasight AS Total Operating Expense Related Terms

Curasight AS Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Curasight AS's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curasight AS Total Operating Expense Chart

Curasight AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 3.94 7.47 7.49 7.64 5.92

Curasight AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 1.31 1.47 1.63 2.20
XSAT:CURAS
24GF Score
Curasight AS XSAT:CURAS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curasight AS Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr6.61 Mil mean?
Curasight AS (XSAT:CURAS) has a Total Operating Expense of kr6.61 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Curasight AS and its competitors.
Is Curasight AS's Total Operating Expense too high?
Curasight AS's current Total Operating Expense is kr6.61 Mil. Overall, Curasight AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Curasight AS's Total Operating Expense compare to VRTX and REGN?
Curasight AS's Total Operating Expense of kr6.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Curasight AS and its competitors. Curasight AS's current Total Operating Expense is kr6.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curasight AS stock overvalued right now?
Curasight AS (XSAT:CURAS) has a current Total Operating Expense of kr6.61 Mil. The current Total Operating Expense is kr6.61 Mil. Curasight AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Curasight AS (XSAT:CURAS), the current Total Operating Expense is kr6.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curasight AS Business Description

Other Exchanges CUS:Germany
Address Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
24GF Score

Get the complete analysis for XSAT:CURAS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr16.75
Price